Shock study calls into question decades of intra-aortic balloon counter-pulsation
Results from the IABP-Shock II trial, the largest ever performed in cardiogenic shock, finds no benefit for intra-aortic balloon pump therapy in MI patients, calling into question a practice used for decades with one of the oldest medical devices.
Physicians and medical boards may have to reconsider decades of cardiogenic shock treatment after the highly anticipated IABP-Shock study found no significant benefit in using intra-aortic balloon pump therapy in heart attack patients.
Intra-aortic balloons are among the earliest medical devices, 1st introduced in 1968, and treatment with the device inserted in the aorta is currently the "most widely used mechanical support device in cardiogenic shock," according to a report released from the 2012 European Society of Cardiology Congress in Munich, Germany.
Despite wide use and clinical acceptance, the procedure failed to produce only minimal clinical benefit in the largest trial ever performed in cardiogenic shock, the 600-patient IABP-Shock study.